Safety and Preliminary Efficacy Assessment of AZD7789 in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Study identifier:D9571C00001

ClinicalTrials.gov identifier:NCT05216835

EudraCT identifier:2021-003569-36

CTIS identifier:N/A

Recruiting

Official Title

A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma.

Medical condition

Relapsed or Refractory Classical Hodgkin Lymphoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD7789

Sex

All

Estimated Enrollment

180

Study type

Interventional

Age

16 Years - 101 Years

Date

Study Start Date: 18 Mar 2022
Estimated Primary Completion Date: 31 Aug 2026
Estimated Study Completion Date: 15 Oct 2027

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria